ANNX

Annexin Pharmaceuticals

Market Cap 81.5M

Annexin Pharmaceuticals is a world-leading, biotech company within the Annexin A5 field. The Stockholm-based company was founded in 2014 by Doctor Anna Frostegård and Professor Johan Frostegård, who pioneered the therapeutic potential of Annexin A5 in 2005. Annexin Pharmceuticals lead candidate, ANXV, is a recombinant human Annexin A5. The drug candidate is currently in planning stage for phase I initiation. ANXV has the potential to become a first-in-class therapy, i.e. the first product on the market with a unique mechanism of action, in several cardiovascular diseases. The company has an agile organization that works in close collaboration with a wide network of external and experienced consultants. Annexin Pharmaceuticals is listed on the OMX Nasdaq First North market since April 2017.

+ more

Community Posts

Be the first to write something about this company in the community.

Create new post